Concepedia

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

Simona Lapusan, María‐Belén Vídriales, Xavier Thomas, Stéphane de Botton, Anne Vekhoff, Ruoping Tang, Charles Dumontet, Rodica Morariu-Zamfir, John M. Lambert, Marie-Laure Ozoux,

Investigational New Drugs · 2011 · 104 citations · 10 references

DOI

Concepts

References

10

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.6K citations

, , +18

Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing

Hans K. Erickson, Peter U. Park, Wayne C. Widdison et al. · Cancer Research · 2006 · 566 citations · Full text

, , +19

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate

Eric L. Sievers, F R Appelbaum, Ricardo Spielberger et al. · Blood · 1999 · 456 citations

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate

Eric L. Sievers, Frederick R. Appelbaum, Ricardo Spielberger et al. · Blood · 1999 · 437 citations

Tumor inhibitors. LXXIII. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus

S. Morris Kupchan, Yasuo Komoda, William A. Court et al. · Journal of the American Chemical Society · 1972 · 426 citations

, , +17